Results 1 to 10 of about 677,032 (302)

Hesitance and Misconceptions about the Annual Influenza Vaccine among the Saudi Population Post-COVID-19

Vaccines, 2023
(1) Background: Vaccination is a cornerstone of public health strategy for mitigating the morbidity and mortality associated with seasonal influenza. However, vaccine hesitancy and misconceptions pose significant barriers to this effort, particularly in ...
Baraa Alghalyini, Tala Garatli, Reela Hamoor, Linda Ibrahim, Yara Elmehallawy, Dima Hamze, Zain Abbara, Abdul Rehman Zia Zaidi   +7 more
doaj   +2 more sources

Evaluation of the field-protective effectiveness of seasonal influenza vaccine among Korean children aged < 5 years during the 2014–2015 and 2015–2016 influenza seasons: a cohort study

Human Vaccines & Immunotherapeutics, 2019
Background: A field effectiveness evaluation of the influenza vaccine among children younger than five years is important due to the high burden of influenza in this age group. The epidemiology of influenza virus changes rapidly each year.
Young Kyung Kang, Hea Lin Oh, Jung Sub Lim, Jun Ah Lee, Yun Kyung Kim, Byung Wook Eun, Dae Sun Jo, Dong Ho Kim   +7 more
doaj   +1 more source

Development and Regulation of Novel Influenza Virus Vaccines: A United States Young Scientist Perspective

Vaccines, 2018
Vaccination against influenza is the most effective approach for reducing influenza morbidity and mortality. However, influenza vaccines are unique among all licensed vaccines as they are updated and administered annually to antigenically match the ...
Surender Khurana
doaj   +1 more source

Vaccine hesitancy and influenza beliefs among parents of children requiring a second dose of influenza vaccine in a season: An American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) study

Human Vaccines & Immunotherapeutics, 2020
To receive adequate protection against influenza, some children 6 months through 8 y old need two doses of influenza vaccine in a given season. Currently, only half of those receiving the first dose receive a second.
Ekaterina Nekrasova, Melissa S. Stockwell, Russell Localio, Justine Shults, Chelsea Wynn, Laura P. Shone, Lindsay Berrigan, Chelsea Kolff, Miranda Griffith, Andrew Johnson, Alessandra Torres, Douglas J. Opel, Alexander G. Fiks   +12 more
doaj   +1 more source

The Usage of Influenza Vaccine to Prevent Seasonal Influenza during Pandemic COVID-19

Magna Medika, 2021
Influenza is an acute respiratory disease caused by influenza virus. Influenza can affect million people in every year and causing morbidity. Some of cases can be severe and need hospitalized, especially in elderly people.
Yelvi Levani, Ayu Lidya Paramita
doaj   +1 more source

Cell culture-derived flu vaccine: Present and future

Human Vaccines & Immunotherapeutics, 2018
The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV ...
Alberto Pérez Rubio, Jose María Eiros
doaj   +1 more source

Safety and Immunogenicity of an Additional Dose of Thailand Government Pharmaceutical Organization (GPO) Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Administered After Primary Vaccination with HXP-GPOVac or BNT162b2: An Open-Label Phase II Extension Trial in Thai Adults

Vaccines
Background/Objectives: Waning immunity after primary COVID-19 vaccination supports evaluation of additional doses. HXP-GPOVac is an egg-based, inactivated Newcastle disease virus (NDV)-vectored vaccine expressing a prefusion-stabilized SARS-CoV-2 HexaPro
Prabda Praphasiri, Darunee Ditsungneon, Anusak Kerdsin, Sutthichai Nakphook, Jiraphut Kittiwatanachod, Kanlaya Sornwong, Suriya Naosri, Sarunpattori Khunarsa, Ponthip Wirachwong, Isariya Techatanawat, Piengthong Narakorn, Somchaiya Surichan, Jorge Flores, Laina D. Mercer, Christina S. Polyak, Bruce L. Innis, Rama Raghunandan, Chakrarat Pittayawonganon, Sopon Iamsirithaworn, Supakit Sirilak, Kriengkrai Prasert   +20 more
doaj   +1 more source

Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics

Frontiers in Microbiology, 2020
Influenza virus is a respiratory pathogen that can cause disease in humans, with symptoms ranging from mild to life-threatening. The vast majority of influenza virus infections in humans are observed during seasonal epidemics and occasional pandemics ...
Olivia A. Vogel, Balaji Manicassamy
doaj   +1 more source

Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins

Nature Communications
Conserved epitopes shared between virus subtypes are often subdominant, making it difficult to induce broadly reactive antibodies by immunization. Here, we generate a plasmid DNA mix vaccine that encodes protein heterodimers with sixteen different ...
Daniëla Maria Hinke, Ane Marie Anderson, Kirankumar Katta, Marlene Fyrstenberg Laursen, Demo Yemane Tesfaye, Ina Charlotta Werninghaus, Davide Angeletti, Gunnveig Grødeland, Bjarne Bogen, Ranveig Braathen   +9 more
doaj   +1 more source

Disease Burden and Inpatient Management of Children with Acute Respiratory Viral Infections during the Pre-COVID Era in Germany: A Cost-of-Illness Study

Viruses
Respiratory viral infections (RVIs) are common reasons for healthcare consultations. The inpatient management of RVIs consumes significant resources. From 2009 to 2014, we assessed the costs of RVI management in 4776 hospitalized children aged 0–18 years
Maren Alchikh, Tim O. F. Conrad, Patrick E. Obermeier, Xiaolin Ma, Brunhilde Schweiger, Onya Opota, Barbara A. Rath   +6 more
doaj   +1 more source